Filing Summary
Issuer identity discrepancy: The supplied filing is Owens & Minor, Inc.’s Form 10-Q, not a filing for ACCENDRA HEALTH INC. Verify the issuer before relying on this summary.
Business Context and Reporting Period
Quarter ended March 31, 2012; comparison is with the three months ended March 31, 2011. Owens & Minor describes itself as a national distributor of medical and surgical supplies and a healthcare supply-chain management company. Financial amounts below are in U.S. dollars; millions are used unless noted.
Financial Performance and Position
| Metric | Q1 2012 | Comparable period / change |
|---|---|---|
| Net revenue | $2,217.9 million | $2,123.8 million; up 4.4% |
| Gross margin | $214.3 million; 9.66% of revenue | $210.8 million; 9.92%; margin down 26 basis points |
| Operating earnings | $51.9 million; 2.34% of revenue | $51.0 million; 2.40%; earnings up 1.7% |
| Net income | $29.4 million | $28.7 million; up 2.2% |
| Diluted EPS | $0.46 | $0.45 |
| Operating cash flow | $101.9 million | $44.5 million |
| Cash and cash equivalents | $213.9 million at March 31 | $135.9 million at December 31, 2011 |
| Debt | $212.3 million long-term debt on the balance sheet | $212.7 million at December 31, 2011 |
Current assets were $1,503.8 million and current liabilities $692.3 million at March 31, implying working capital of approximately $811.5 million and a current ratio of approximately 2.17. The company had $345 million available under its $350 million revolving facility, with $5 million of letters of credit and no borrowings. Senior notes have $200 million principal, mature in April 2016, and bear interest at 6.35%. The company reported compliance with debt covenants.
Material Changes and Cash Flow
- Revenue growth came from existing customers (+$55.9 million), net new customers (+$33.1 million), and fee-for-service revenue (+$5.1 million).
- Gross margin percentage declined mainly because of customer mix, including lower-margin large integrated health network contracts, and competitive pressure. Gross margin benefited from a $6.0 million year-over-year improvement in the LIFO provision comparison; traditional distribution margin decreased $0.6 million.
- SG&A rose 3.0% to $155.6 million, including higher costs to serve fee-for-service and new third-party logistics business. Lower incentive compensation, consulting, selling and occupancy costs partly offset higher warehouse and fuel costs.
- Operating cash flow increased substantially, supported by lower inventory and improved receivable collection; the company said inventory had been built up in Q4 2011 for large customer conversions and returned to normalized levels in Q1. Cash flow also reflected a $38.3 million decrease in accounts payable.
- Investing cash use was $8.3 million, including $4.5 million for property and equipment and $3.8 million for software and intangible assets. Financing cash use was $15.6 million, including $14.0 million of dividends and $3.8 million of share repurchases, partly offset by stock-option proceeds.
Outlook, Risks, and Unusual Items
- No specific earnings or revenue guidance is provided. Management expects available cash, operating cash generation and revolver access to be sufficient for working capital, capital spending, debt and lease payments, dividends, repurchases and other needs. It anticipates continuing quarterly dividends, subject to Board discretion.
- An April 2012 Novation distribution agreement, effective September 1, 2012, will replace the existing agreement. It preserves Owens & Minor’s status as an authorized distributor but requires competition for member business; the term is five years, with two one-year renewal options.
- Q1 2012 other operating income included $0.5 million related to settlement of class-action litigation. Other operating income was $1.7 million, compared with a small expense in Q1 2011.
- A $12.7 million exit and realignment charge was recorded in Q4 2011; the remaining exit-cost accrual was $8.6 million at March 31, 2012. The retirement plan was amended and frozen effective March 31, producing a $0.2 million curtailment loss.
- Potential customer performance payments of $2.5 million were not accrued because management did not consider them probable. A California sales-tax incentive review could yield a contingent gain of up to $7.4 million; no receipt is assured.
- Management identifies risks including competition, customer retention and concentration, supplier programs and pricing, healthcare regulation, contract performance, fuel costs, financing access and rates, information-system disruption, litigation and tax matters. Diesel averaged $3.96 per gallon versus $3.61 a year earlier; management estimated each 10-cent benchmark increase reduced annual operating earnings by about $470,000, excluding mitigation. A fixed-price agreement covers approximately one-third of expected 2012 fuel use at a $3.90 benchmark equivalent.
- Disclosure controls were assessed as effective at March 31, 2012; the filing reports no material change in internal control over financial reporting during the quarter. No material developments in previously disclosed legal proceedings or risk factors were reported.
Important Facts for Investors to Verify
- Confirm that Owens & Minor, Inc.—rather than ACCENDRA HEALTH INC.—is the intended issuer and filing.
- Assess whether revenue growth can continue while gross margin percentage remains under pressure from customer mix and competition.
- Review the quality and sustainability of the operating cash flow increase, particularly the inventory normalization and working-capital movements.
- Monitor the Novation agreement’s effect on member business, customer retention and margins after its September 2012 effective date.
- Track revolver renewal or extension ahead of its June 2013 expiration, covenant compliance, fuel exposure, and the status of contingent customer payments and the California tax incentive review.